Lifestyle Counseling & Risk Reduction
Meeting patients where they are — the behavior-change toolkit
The counseling framework: 5 A's, readiness, and motivational interviewing
The 5 A's. Brief counseling for tobacco (and most risky behaviors) follows five steps; "assist" means medication plus counseling, not either one alone.
- AskScreen every patient for tobacco use and document it.
- AdviseGive a clear, strong, personalized urge to quit.
- AssessGauge willingness to make a quit attempt now.
- AssistOffer pharmacotherapy plus counseling; set a quit date if ready.
- ArrangeSchedule follow-up contact, ideally within the first week after the quit date.
The 5 R's. For a patient not yet willing to quit, build motivation with Relevance (why quitting matters to this patient), Risks of continuing, Rewards of quitting, Roadblocks to address, and Repetition at every visit.
Stages of change. The transtheoretical model stages readiness to change, and the intervention should match the stage. Relapse is expected and is part of the cycle, not a failure.
| Stage | Patient's stance | Clinician's focus |
|---|---|---|
| Precontemplation | Not considering change | Raise awareness, personalize risk, use the 5 R's, keep the door open |
| Contemplation | Ambivalent, weighing pros and cons; thinking about change within about 6 months ("I know I should quit, but I'm not ready") | Motivational interviewing to explore and resolve ambivalence |
| Preparation | Planning to act within a month; quit date set | Build a concrete plan, start pharmacotherapy |
| Action | Actively changing | Support, coping skills, manage withdrawal and triggers |
| Maintenance | Change sustained (beyond about 6 months) | Reinforce gains, plan for high-risk situations, treat relapse as part of the cycle |
Motivational interviewing (MI). MI is a collaborative, nonjudgmental style that draws out the patient's own reasons for change. Its four principles are to express empathy, develop discrepancy (between current behavior and the patient's goals), roll with resistance (do not argue or confront), and support self-efficacy. The core skills are OARS: Open questions, Affirmations, Reflective listening, and Summarizing.
When a patient resists, reflect and explore the ambivalence; lecturing about cancer, insisting on a quit date today, or referring away all run against MI.
Tobacco cessation pharmacotherapy
Varenicline. A partial agonist at the α4β2 nicotinic acetylcholine receptor, varenicline is the most effective single agent. It eases craving and withdrawal while blunting the reward from smoking. Nausea is the most common side effect; vivid dreams and insomnia also occur.
Bupropion. A norepinephrine–dopamine reuptake inhibitor that also treats coexisting depression and blunts weight gain. It lowers the seizure threshold: avoid with seizure or eating disorders (bulimia, anorexia).
Nicotine replacement therapy (NRT). Pair a long-acting patch with a short-acting form (gum, lozenge, inhaler, nasal spray); combining agents raises quit rates. NRT is safe in stable cardiovascular disease.
In pregnancy, behavioral counseling is first-line; the USPSTF finds the evidence insufficient for cessation pharmacotherapy in pregnancy and for e-cigarettes as a cessation tool in adults.
Alcohol: screening and treatment
SBIRT (Screening, Brief Intervention, Referral to Treatment) is the primary-care model: screen all adults, intervene briefly for risky drinking, and refer when alcohol use disorder (AUD) is likely.
Screening tools. CAGE covers the need to Cut down, being Annoyed by criticism, Guilt, and an Eye-opener; two or more positive answers suggest problem drinking. The AUDIT-C (three consumption questions) is also validated.
| Drug | Mechanism | Role | Cautions |
|---|---|---|---|
| Naltrexone | Opioid receptor antagonist; reduces craving and the reward of drinking | First-line (oral or monthly IM depot) | Avoid with any opioid use (precipitates withdrawal) or acute hepatitis |
| Acamprosate | Modulates glutamate (NMDA) signaling | First-line to maintain abstinence; preferred in liver disease | Renally cleared; avoid in severe renal impairment |
| Disulfiram | Inhibits aldehyde dehydrogenase, so acetaldehyde builds up | Aversive; only for highly motivated, supervised patients | Flushing, nausea, vomiting with any alcohol; hepatotoxicity |
Obesity, physical activity, and diet
Classification. BMI 25–29.9 is overweight and ≥30 is obese (class III or severe obesity is ≥40). Start every patient on diet, exercise, and behavior change.
Pharmacotherapy. Add a medication at BMI ≥30, or ≥27 with a weight-related comorbidity, always alongside lifestyle therapy. All of these drugs are contraindicated in pregnancy.
- GLP-1 receptor agonists (semaglutide, liraglutide) and tirzepatide (dual GIP/GLP-1 agonist) give the largest weight loss. Expect GI upset; avoid with a personal or family history of medullary thyroid carcinoma or MEN2.
- Phentermine-topiramate is a sympathomimetic plus an anticonvulsant. It is teratogenic; avoid it with uncontrolled hypertension or heart disease.
- Naltrexone-bupropion: avoid with seizure disorders or opioid use.
- Orlistat is a lipase inhibitor that causes steatorrhea and fat-soluble vitamin malabsorption.
Bariatric surgery. Consider surgery at BMI ≥40, or ≥35 with an obesity-related comorbidity (type 2 diabetes, obstructive sleep apnea, hypertension), once lifestyle measures have failed. Roux-en-Y gastric bypass and sleeve gastrectomy give durable weight loss and frequent diabetes remission. After bypass, patients need lifelong supplements (B12, iron, calcium, vitamin D, folate, thiamine).
Newer surgical society guidance (2022) widens eligibility to BMI ≥35 regardless of comorbidity and to BMI 30–34.9 with metabolic disease; the classic 40 / 35-plus-comorbidity thresholds remain the traditional exam answer.
Activity and diet targets. Recommend at least 150 minutes per week of moderate aerobic activity (or 75 minutes vigorous), plus muscle strengthening on 2 or more days per week. Favor Mediterranean or DASH patterns: vegetables, fruit, whole grains, and lean protein, with less sodium and processed food.
Contraception counseling
Counsel by efficacy tier. The most effective methods do not depend on daily or per-act adherence.
| Tier | Methods | Key point |
|---|---|---|
| Most effective | LARC: etonogestrel implant, levonorgestrel or copper IUD; sterilization | User-independent; under 1 pregnancy per 100 women per year |
| Intermediate | Pills, patch, ring, injection | User-dependent; typical-use failure well above perfect use |
| Least effective | Condoms, withdrawal, fertility-awareness methods (FAM) | Depend on correct use with every act |
When estrogen is off the table. Estrogen-containing methods are MEC category 4 (unacceptable risk) with:
- Migraine with aura (ischemic stroke risk)
- Age ≥35 and smoking ≥15 cigarettes per day
- History of VTE or stroke, or a known thrombogenic mutation
- Hypertension with systolic ≥160 or diastolic ≥100 (140 to 159 or 90 to 99 is MEC 3)
- Current breast cancer
- Less than 3 weeks (21 days) postpartum
Use a progestin-only method (pill, implant, injection, levonorgestrel IUD) or a copper IUD instead. Current breast cancer is MEC 4 for all hormonal methods, so only the copper IUD is appropriate.
Emergency contraception. Every method works best the sooner it is used.
- Copper IUDMost effective; insert within 5 days; also provides ongoing contraception.
- Ulipristal acetateOral progesterone receptor modulator, effective up to 5 days; more effective than levonorgestrel, especially at higher body weight; prescription only.
- Levonorgestrel (Plan B)Best within 72 hours; over the counter; less effective with higher body weight.
After ulipristal, wait 5 days before starting hormonal contraception (a progestin can blunt its effect) and use a barrier method as backup meanwhile.